LOCARNO, Switzerland -- (BUSINESS WIRE) -- Linnea SA, a high-quality manufacturer of active ingredients for use in the health food, cosmetic, and pharmaceutical industries, announced that “Pharmacokinetics and Bioavailability of Plant Lignan 7-Hydroxymatairesinol and Effects on Serum Enterolactone and Clinical Symptoms in Postmenopausal Women: A Single-Blinded, Parallel, Dose-Comparison Study” has been published in the Journal of the American College of Nutrition. The Principal Investigator of the study, Dr. Jay Udani of Medicus Research, said “Not only was the HMRlignan quickly absorbed into the blood, but it was metabolized effectively into Enterolactone which is the form of the ingredient that is useful in humans. In the group receiving the higher dose of the product, there was a 55 percent reduction in the number of hot flashes after only 4 weeks and these women continued to report a 50 percent reduction in hot flashes through 8 weeks. The product was well tolerated throughout the study and these results point toward this product being of potential benefit to women looking to reduce their hot flashes.”
Postmenopausal females ages 50-75, who were not receiving hormone replacement therapy (HRT), were enrolled in either a 36 mg/d (low-dose) or 72 mg/d dose (high-dose) regimen for eight weeks. Following a single dose of 36 mg of HMRlignan, maximum plasma levels of 7-HMR were reached in one hour. Maximum plasma levels of Enterolactone were reached in 24 hours, suggesting that the ingredient can be taken once daily. In the 72 mg/day group, there was a 55 percent reduction in hot flashes at week four and 80 percent fewer severe hot flashes at week eight, with no adverse events noted, and no estrogenic effects measured through blood tests.
“The results of this study hold promise for the potential of a low-dose lignan supplement such HMRlignan to aid in relief of the symptoms associated with menopause without the adverse effects of HRT,” said Donald Brown, ND, Managing Director of Natural Product Research Consultants.
A follow-up 12-week study with a larger cohort of postmenopausal women is currently underway to study the effects of HMRlignan on hot flashes.
About Linnea SA of Switzerland
Located in the Swiss canton of Ticino, Linnea is a high-quality manufacturer of active ingredients for use in the health food and cosmetic industries and pharmaceutical industries. Linnea specializes in the extraction and purification of plant materials and the synthesis of fine chemicals. The company employs a team of 90 experienced professionals with expertise in the manufacture of botanical extracts and active pharmaceutical ingredients. The company’s products are obtained from an exclusive selection of raw materials and onsite controls. Each extract is standardized to a high level of purity in compliance with current Monographs and according to ICH GMP operating standards. Drug Master File (DMF) is available for APIs and herbal extracts.